TAK-781

RNA / oligonucleotide

Phase 1Mechanism not established

Automated registry profile: compiled from public clinical-trial and regulatory records; not yet individually analyst-verified.

Earlyevidence

Evidence outlook

Early-stage evidence only

Phase 1 / first-in-human studies establish safety, tolerability, and dosing; they are not designed to demonstrate efficacy, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 1 (1)
Primary Sclerosing Cholangitis
NCT07229911 · Takeda
2026-01-07 – 2028-04-06 · Healthy Volunteers, Primary Sclerosing Cholangitis
What this study did

Competitive landscape

This drug's own stage for Primary Sclerosing Cholangitis: Phase 1. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
TAK-781: this drugPhase 1RNA / oligonucleotide—not yet gradedNo reviewed efficacy summary in this indication
VolixibatPhase 2Small moleculeIleal bile acid transporter (IBAT)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow TAK-781 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (1)
April 2028 (1)
Phase 1Primary Sclerosing CholangitisRecruiting
Est. primary completion 2028-04-06 · NCT07229911 · CT.gov ↗
What to watch

See the full readout calendar ↗